NCT01854996View on ClinicalTrials.gov

Relative Bioavailability With PF-05089771 Capsule Versus Oral Dispersion

PHASE1CompletedINTERVENTIONAL

Enrollment

12

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Healthy

Interventions

DRUG

PF-05089771

450mg

DRUG

PF-05089771

450mg

DRUG

PF-05089771

450mg

Trial Locations (1)

B-1070

Pfizer Investigational Site, Brussels

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Pfizer

INDUSTRY